Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> MutationsLecia V. Sequist, Martin Schüler, James Chih‐Hsin Yang et al.|Journal of Clinical Oncology|2013Cited by 3.2k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih‐Hsin Yang, Lecia V. Sequist, Yi‐Long Wu et al.|The Lancet Oncology|2015Cited by 1.6k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal CancerTakashi Kojima, Manish A. Shah, Kei Muro et al.|Journal of Clinical Oncology|2020Cited by 1.2k
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic CancerEric Van Cutsem, Malcolm J. Moore, Walter L. Vervenne et al.|Journal of Clinical Oncology|2009Cited by 643
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Patrick A. Ott, Sarina A. Piha‐Paul et al.|Journal of Thoracic Oncology|2019Cited by 437